Navigation Links
Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
Date:5/7/2008

FREDERICK, Md., May 7 /PRNewswire/ -- Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than $100 million of potential European sales.

The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial -- the final step before the vaccine can be sold in the United States.

"The facility can produce up to 3,500 vaccines annually, equivalent to $130 million in revenues," said Michael G. Hanna, Jr., Ph.D., Vaccinogen CEO. "That number only scratches the surface of potential demand for a Stage II colon cancer vaccine. One of every three patients who have their cancer removed see it return -- and the results are usually fatal."

"Our experience with OncoVAX has resulted in increasing the patients' chance of survival by more than 50%," he concluded. "This represents an opportunity for a new lease on life for tens of thousands of patients around the world."

The Dutch license permits the company to commercialize the vaccine, first in Switzerland and then in seven other countries in Eastern Europe. The OncoVAX vaccine represents a potential medical breakthrough because it uses a patient's own cancer cells to prevent the cancer from returning after a successful operation to remove it.

"This manufacturing license being granted by the most stringent and respected biotech manufacturing reviewers in Europe is a major milestone for Vaccinogen as it begins to generate revenues from OncoVAX," Dr. Hanna said. "It's also a major leap towards the worldwide acceptance of individualized cancer vaccines."

About OncoVAX

OncoVAX immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.

About Vaccinogen

Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products -- Turning Cancer on Itself(TM). Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development.

http://www.vaccinogeninc.com

Vaccinogen's online press kit: http://www.vaccinogeninc.com/press_kit.cfm

Contact:

Andrew L. Tussing

Vaccinogen

atussing@vaccinogeninc.com

301-668-8400


'/>"/>
SOURCE Vaccinogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
2. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
3. Childrens Hospitals in Washington to Lobby Congress to Reauthorize SCHIP Now
4. American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback
5. QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value
6. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
7. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
8. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
9. Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs
10. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
11. 5,000 Northern California Nurses to Vote to Authorize Third Strike Against Sutter Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... ... 2016 , ... On Memorial Day, Hope For Heroes and USA ... battle for the country. The nonprofit Hope For Heroes partnered with the leading ... independence for disabled military veterans, as well as police, firemen, and EMS professionals across ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... MadgeTech will ... designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products ... reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
Breaking Medicine Technology: